BTIG initiated coverage of Praxis Precision (PRAX) with a Buy rating and $424 price target The firm, which sees a greater than $5B greenfield opportunity for ulixacaltamide in essential tremor, also notes that Praxis also has a pair of sodium channel modulators, vormatrigine and relutrigine, with positive Phase 2 data in epilepsy and developmental and epileptic encephalopathy, respectively.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Optimistic Outlook for Praxis Precision Medicines: Promising Drug Pipeline and Strategic Advancements Drive Buy Rating
- Praxis Precision price target raised to $258 from $232 at H.C. Wainwright
- Promising Growth Potential for Praxis Precision Medicines: Ulixacaltamide’s Breakthrough in Essential Tremor Treatment
- Praxis Precision participates in a conference call with H.C. Wainwright
- Praxis Precision announces inducement grants under Nasdaq lsiting rule